11205) or guanine monophosphate synthetase (GMPS; EC 6352) t

1.1.205) or guanine monophosphate synthetase (GMPS; EC 6.3.5.2) to produce 6-TGNs (Fig. 1).30 As yet the only support TGF-beta inhibitor for this hypothesis is the discovery of a 9 bp insertion within the promoter of IMPDH1 in an IBD patient who exhibited preferential 6-MMPR metabolism.31 The insertion, predicted to abolish a cAMP-response

element (CRE), significantly reduced gene expression in vitro (P-value < 0.001).31 Polymorphisms within xanthine oxidase (XO; EC 1.1.1.204), aldehyde oxidase (AOX1; EC 1.2.3.1) and hypoxanthine phosphoribosyl transferase (HPRT; EC 2.4.2.8) (Fig. 1), may contribute to non-response to azathioprine and 6-mercaptopurine. Several recent reports in the literature support this argument. A case report of a patient with unusually high XO activity, who was non-responsive to azathioprine, but produced toxic concentrations of 6-TGNs and 6-MMPR on a combination of 6-mercaptopurine and the XO inhibitor allopurinol demonstrates that elevated XO activity can cause thiopurine non-response.32 Although not explored, it is possible that the unusually high XO activity observed in this patient had a genetic basis. Lending weight

to this possibility is the discovery of gain-of-function SNPs which caused a significant increase in XO activity in vitro.33 In addition to XO, there is also preliminary evidence to suggest that alterations in AO may cause thiopurine non-response. Smith et al.34 reported association of a non-synonymous SNP in the

AOX1 gene with lack of clinical response to azathioprine. IBD patients who were heterozygous or homozygous for the minor allele of AOX1 Selleck INCB024360 c.3404A>G (Asn1135Ser) were significantly more likely to be refractory to azathioprine therapy than patients without this SNP (17% vs 34%; P = 0.035, OR = 2.54, 95% CI: 1.06–6.13).34 Genetic polymorphisms in a molecular target of thiopurine therapy.  Research has demonstrated that one of the 6-TGNs, 6-thioguanine triphosphate (6-TGTP) (Fig. 1), contributes significantly to the overall immunosuppressive effect of thiopurine therapy by binding to the small guanosine triphosphatase (GTPase) RAC1 on CD28 costimulation in CD4+ T cells.35 Binding of 6-TGTP to RAC1 blocks Vav exchange activity leading to the disruption of the Vav1-Rac1 signaling cascade and a therapeutic reduction in inflammation.36 As RAC1 is an Gefitinib ic50 important molecular target of thiopurine metabolites it is possible that genetic polymorphisms that alter the expression or function of this GTPase may influence patient response to azathioprine and 6-mercaptopurine. Bourgine et al.37 have provided the first evidence for the existence of functional polymorphisms within the promoter of the RAC1 gene. Using a combination of PCR-single strand conformation polymorphism analysis and DNA sequencing, Bourgine et al.37 identified a total of 16 RAC1 polymorphisms across 92 healthy controls and 128 IBD patients receiving azathioprine.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>